Sugi Predict

Sugi Predict / Compounds / SCHEMBL786356

SCHEMBL786356

SCHEMBL786356

CCCCCCCC/C=C\CCCCCCCCN(CCCCCCCC/C=C\CCCCCCCC)C(P)(CO)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 3/20 0.47
▸ TERT O14746 3/20 0.46
▸ PTPN1 P18031 3/20 0.46
▸ PPARG P37231 3/20 0.46
▸ PPARD Q03181 3/20 0.46
▸ PPARA Q07869 3/20 0.46
▸ TOP1 P11387 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ BLM P54132 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ FABP4 P15090 2/20 0.46
▸ GMNN O75496 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5486195 0.91 GPR84 (0.36) PTPN1PPARGPPARDPPARAHSD17B10
SCHEMBL1271901 0.84 PPARG (0.53) EPHX2TERTPTPN1PPARGPPARD
SCHEMBL456745 0.84 PPARG (0.53) EPHX2TERTPTPN1PPARGPPARD
SCHEMBL1470099 0.84 PPARG (0.53) EPHX2TERTPTPN1PPARGPPARD
SCHEMBL739160 0.76 EPHX2 (0.49) EPHX2TERTPTPN1PPARGPPARD
SCHEMBL5186415 0.73 EPHX2 (0.47) EPHX2TERTPTPN1PPARGPPARD
SCHEMBL5495040 0.73 GPR84 (0.44) PTPN1PPARGPPARDPPARAMAPT
SCHEMBL30413 0.73 GPR84 (0.44) PTPN1PPARGPPARDPPARAMAPT
SCHEMBL5490197 0.73 GPR84 (0.44) PTPN1PPARGPPARDPPARAMAPT
SCHEMBL739159 0.72 TERT (0.51) EPHX2TERTPTPN1PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-8003072-A — — None — — JP disclosed
US-11839590-B2 Flurbiprofen axetil emulsion for injection and preparation method thereof Grand life science (wuhan) co., LTD (CN) 2023-12-12 — — US disclosed
US-20220117932-A1 Lecithin Vesicles CannaClear Inc. (CA) 2022-04-21 — — US disclosed
US-20220023214-A1 Lecithin Vesicles for Oral Delivery CannaClear Inc. (CA) 2022-01-27 — — US disclosed
US-11154502-B2 Lecithin vesicles for oral delivery CannaClear Inc. (CA) 2021-10-26 — — US disclosed
US-20210220303-A1 FLURBIPROFEN AXETIL EMULSION FOR INJECTION AND PREPARATION METHOD THEREOF GRAND LIFE SCIENCE (WUHAN) CO., LTD. (CN) 2021-07-22 — — US disclosed
EP-3819640-A1 LIPOSOME-CONTAINING LIQUID REAGENT FOR MEASURING BLOOD COAGULATION ABILITY LSI Medience Corporation (JP) 2021-05-12 — — EP disclosed
US-20210093565-A1 VESICLE-ENCAPSULATED SOCS THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2021-04-01 — — US disclosed
EP-3787670-A1 INDUCTION OF ALLERGEN-SPECIFIC TREGS PRIOR TO ORAL OR SUBLINGUAL IMMUNOTHERAPY OF FOOD ALLERGY Luxembourg Institute of Health (LIH) (LU) 2021-03-10 — — EP disclosed
EP-3723863-A1 HYDROGEL-EMBEDDED OLIGODEOXYNUCLEOTIDES AS TOLEROGENIC ADJUVANT FOR SUBCUTANEOUS IMMUNOTHERAPY Luxembourg Institute of Health (LIH) (LU) 2020-10-21 — — EP disclosed
EP-2435031-A1 FUNCTIONAL AMPHIPHILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS Université Bordeaux Segalen (FR) 2012-04-04 — — EP disclosed
US-20120070505-A1 FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS UNIVERSITE DE LA MEDITERRANEE (FR) 2012-03-22 — — US disclosed
US-20110059180-A1 Method for Preparing Nanoparticles Based on Functional Amphiphilic Molecules or Macromolecules, and the Use Thereof Universite de Bordeaux (FR) 2011-03-10 — — US disclosed
WO-2010136676-A1 FUNCTIONAL AMPHIPHILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS UNIVERSITE VICTOR SEGALEN BORDEAUX 2 (FR) 2010-12-02 — — WO disclosed
EP-2231132-A2 METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF Université Victor Segalen Bordeaux 2 (FR) 2010-09-29 — — EP disclosed
WO-2009098404-A2 METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF UNIVERSITE VICTOR SEGALEN BORDEEUX 2 (FR) 2009-08-13 — — WO disclosed
WO-2007059852-A1 PH-SWITCHABLE TRANSMEMBRANE PEPTIDES AS STIMULATORS OF MEMBRANE FUSION Technische Universität München (DE) 2007-05-31 — — WO disclosed
EP-1790657-A1 pH-switchable transmembrane peptides as stimulators of membrane fusion Technische Universität München (DE) 2007-05-30 — — EP disclosed
JP-H083072-A PERCUTANEOUS ABSORBEFACIENT AND EXTERNAL AGENT FOR SKIN POLA CHEM IND INC 1996-01-09 — — JP disclosed
US-5049388-A Small particle aerosol liposome and liposome-drug combinations for medical use RESEARCH DEVELOPMENT FOUNDATION (US) 1991-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059180-A1 Method for Preparing Nanoparticles Based on Functional Amphiphilic Molecules or Macromolecules, and the Use Thereof CETP, PCTP, ABCB4 EPHX2 1213/4885TERT 3568/4885PTPN1 2474/4885
US-20120070505-A1 FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS ANXA2, SLC47A2, ABCB4 EPHX2 2850/4885TERT 4045/4885PTPN1 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.